{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-scalp/prescribing-information/oral-terbinafine/","result":{"pageContext":{"chapter":{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine","depth":2,"htmlHeader":"<!-- begin field 5b0565e0-d5aa-41fd-bc96-874498e1db57 --><h2>Oral terbinafine</h2><!-- end field 5b0565e0-d5aa-41fd-bc96-874498e1db57 -->","summary":"","htmlStringContent":"<!-- begin item d0c033fa-8331-4a1d-aa9e-005380350843 --><!-- end item d0c033fa-8331-4a1d-aa9e-005380350843 -->","topic":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da","topicId":"0fd8e2d0-69ae-41e6-b283-543453f673bc","topicName":"Fungal skin infection - scalp","slug":"fungal-skin-infection-scalp","lastRevised":"Last revised in April 2018","chapters":[{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"97441633-de03-58fd-9e1b-bb42c2828337","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7bc5a70d-2277-5bff-9951-bb0c0ab337ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f9145ac8-339e-59bb-b8ad-25b709acdacb","slug":"changes","fullItemName":"Changes"},{"id":"d0c182d2-7ce4-57e0-9dee-362b0b530365","slug":"update","fullItemName":"Update"}]},{"id":"6f048cdd-1cbb-5611-a5e0-8361b221db8a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"599dbe6a-d7a3-5f91-91ed-4be709b1180c","slug":"goals","fullItemName":"Goals"},{"id":"84c3bfe1-6c40-57e4-a749-77a9946a89e3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ac49d0bf-50dc-5071-a82b-62723de01de5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"60065f70-8af3-5f60-9dca-ff069607e2bc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fba31ad2-44ba-5fe6-bf46-7345ab044a0e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d12ccb71-eddd-5517-8749-1217ba0b4eb6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba0c5ffb-2309-5d72-90e0-4c09ec2762ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a7a6e00a-8e02-5305-be1d-1aa4389187a5","slug":"definition","fullItemName":"Definition"},{"id":"a7f24440-b63f-56f4-8c94-3bb4b1877412","slug":"prevalence","fullItemName":"Prevalence"},{"id":"015c5679-e685-58cd-b557-2ed3559a9603","slug":"complications","fullItemName":"Complications"},{"id":"8fa3f79d-ba1c-5733-8306-100d8afeabfb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fa2925a0-ec3e-5255-b9f9-7959141a2e82","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b464e67b-56da-51d3-a0d4-4577dd9c24f7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4d8408bc-15aa-5151-a55a-b7849dcb8387","slug":"assessment","fullItemName":"Assessment"},{"id":"67ef57a0-32a1-5271-8ef9-7a7e9e1e5a24","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","fullItemName":"Management","slug":"management","subChapters":[{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"},{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"e6d4f0f1-7501-5b3f-9954-957d8152ffb7","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"cc03af24-7789-56ce-978f-b905a9611cb5","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ce8e8c93-7919-5160-9ad5-965fcd16658f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e05609c9-c42a-5eec-b055-39a296c3e2ea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e4f27b22-bcda-54f2-83f3-4ebf35f962ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0ce2862f-cdca-57b0-9998-9bc40799914a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e057656-6867-5510-95c7-019671326f4b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"687c951d-457b-52b6-93f8-e38d5eafe6ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f17589e6-56a0-535c-aa03-0856855943bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"20a63d90-c53a-5195-bf9f-a38a5e66c0c2","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 2e2c1aa3-1805-4617-a7f8-a8c50159ee12 --><h3>Dosing schedule</h3><!-- end field 2e2c1aa3-1805-4617-a7f8-a8c50159ee12 -->","summary":"","htmlStringContent":"<!-- begin item 1aeae3e1-a9a0-42ce-9783-a8c50159ecdc --><!-- begin field 64eb5443-865c-4696-b609-a8c50159ee12 --><p><strong>Terbinafine is available in tablet form but not liquid or suspension.</strong></p><ul><li>For children aged 1–17 years:<ul><li>Bodyweight 10–19 kg, prescribe 62.5 mg once daily for 4 weeks.</li><li>Bodyweight 20–39 kg, prescribe 125 mg once daily for 4 weeks.</li><li>Bodyweight 40 kg and above, prescribe 250 mg once daily for 4 weeks.</li></ul></li><li>For adults, prescribe 250 mg once daily for 4 weeks.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>]</p><!-- end field 64eb5443-865c-4696-b609-a8c50159ee12 --><!-- end item 1aeae3e1-a9a0-42ce-9783-a8c50159ecdc -->","subChapters":[]},{"id":"667c22db-ab5d-53b8-9f13-07f732e9f445","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e73d1a1c-f524-4425-9702-a8aa00dc4dc4 --><h3>Contraindications and cautions</h3><!-- end field e73d1a1c-f524-4425-9702-a8aa00dc4dc4 -->","summary":"","htmlStringContent":"<!-- begin item 04e81307-ad55-42c7-8d78-a8aa00dc4ca7 --><!-- begin field fdf4b719-e6bd-4bbb-bf76-a8aa00dc4dc4 --><p><strong>Do not prescribe terbinafine to people with:</strong></p><ul><li>Hepatic impairment — the manufacturer recommends that terbinafine should not be prescribed in people with chronic or active hepatic disease. It recommends for other people, liver function tests (LFTs) should be performed. Hepatotoxicity may occur in people with and without pre-existing hepatic disease, therefore periodic monitoring of LFTs (after 4–6 weeks of treatment) is recommended. Terbinafine should be stopped immediately if LFTs are deranged.</li><li>Severe renal impairment.</li></ul><p><strong>Prescribe terbinafine with caution to people with:</strong></p><ul><li>Autoimmune disease — risk of lupus erythematosus-like effect.</li><li>Psoriasis — increased risk of exacerbation of psoriasis.</li><li>Renal impairment — the BNF recommends that half the normal dose of terbinafine should be used if estimated glomerular filtration rate (eGFR) is less than 50 mL/min/1.73 m<sup>2</sup> and there is no suitable alternative. However, the manufacturer does not recommend using terbinafine in these people, as it has not been adequately studied.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field fdf4b719-e6bd-4bbb-bf76-a8aa00dc4dc4 --><!-- end item 04e81307-ad55-42c7-8d78-a8aa00dc4ca7 -->","subChapters":[]},{"id":"4575b658-d0c9-539e-b042-e86a22add1f8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f084f681-fa23-4cb6-9d2f-a8aa00dc6288 --><h3>Adverse effects</h3><!-- end field f084f681-fa23-4cb6-9d2f-a8aa00dc6288 -->","summary":"","htmlStringContent":"<!-- begin item 7409da46-22bc-47be-a486-a8aa00dc616f --><!-- begin field 3efe0b9f-1172-48db-9c7f-a8aa00dc6288 --><p><strong>Adverse effects of terbinafine include:</strong></p><ul><li>Gastrointestinal — abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea, feeling of fullness (very common); pancreatitis (unknown frequency).</li><li>Nervous system — headache (common); taste disturbance (uncommon). Dizziness, paraesthesia, and hypoaesthesia (rare).</li><li>Skin and subcutaneous tissue — rash, urticarial (very common). Very rarely Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, skin eruption, dermatitis exfoliative, dermatitis bullous, photosensitivity reaction, and alopecia.</li><li>Other common or very common adverse effects include arthralgia, myalgia, decreased appetite.</li><li>Other rare or very rare adverse effects include:<ul><li>Anaphylaxis.</li><li>Hepatic dysfunction, jaundice, hepatitis, cholestasis — people taking terbinafine tablets should be warned to report immediately any signs and symptoms of unexplained persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale faeces. If these symptoms develop, terbinafine treatment should be stopped, and liver function tests (LFTs) should be immediately performed.</li><li>Malaise, neutropenia, agranulocytosis, thrombocytopenia, vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field 3efe0b9f-1172-48db-9c7f-a8aa00dc6288 --><!-- end item 7409da46-22bc-47be-a486-a8aa00dc616f -->","subChapters":[]},{"id":"d3cd72b9-b619-549c-b391-ab0baefed292","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1a47c35d-4900-4ebe-b74b-a8aa00dc7b2c --><h3>Drug interactions</h3><!-- end field 1a47c35d-4900-4ebe-b74b-a8aa00dc7b2c -->","summary":"","htmlStringContent":"<!-- begin item e4b643cc-1923-4e69-b48e-a8aa00dc7a55 --><!-- begin field a59f1bff-403a-4c07-999d-a8aa00dc7b2c --><p><strong>Possible drug interactions with terbinafine include:</strong></p><ul><li>Codeine —<strong> </strong>the analgesic effect may be reduced or abolished by terbinafine. Monitor for analgesic efficacy.</li><li>Rifampicin — levels of terbinafine are reduced. Dose increases of terbinafine may be necessary.</li><li>Tamoxifen — avoid concurrent use. Metabolism to an active metabolite of tamoxifen may be inhibited by terbinafine. </li><li>Terbinafine levels may be increased by the following drugs if taken concomitantly:<ul><li>Amiodarone.</li><li>Fluconazole, ketoconazole.</li></ul></li><li>Terbinafine may increase levels of the following drugs if taken concomitantly, thereby increasing or prolonging their effects, including adverse effects:<ul><li>Anti-arrhythmics (flecainide, mexiletine, and propafenone).</li><li>Aripiprazole, risperidone.</li><li>Beta-blockers (carvedilol, metoprolol, nebivolol, propranolol, and timolol).</li><li>Dextromethorphan.</li><li>Monoamine oxidase inhibitors Type B (MAOIs-B, such as selegiline).</li><li>Selective serotonin reuptake inhibitors (sertraline, paroxetine).</li><li>Tramadol — terbinafine may increase levels of tramadol, but not the active metabolite, which cause an increase in adverse effects, but not in analgesic effect.</li><li>Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline).</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field a59f1bff-403a-4c07-999d-a8aa00dc7b2c --><!-- end item e4b643cc-1923-4e69-b48e-a8aa00dc7a55 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}